Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.39 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.39 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.39 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705585 | 0.89 | ADRA2C (0.41) | HRH4CCNCCDK8DCTPP1NPC1 | |
| SCHEMBL1706540 | 0.83 | HTR1A (0.41) | HRH4CCNCCDK8DCTPP1NPC1 | |
| SCHEMBL1706908 | 0.82 | PLOD2 (0.40) | HRH4DCTPP1NPC1MAPTPLOD2 | |
| SCHEMBL1756052 | 0.81 | PLOD2 (0.43) | CCNCCDK8DCTPP1NPC1MAPT | |
| SCHEMBL1706531 | 0.81 | MEN1 (0.41) | HRH4CCNCCDK8DCTPP1NPC1 | |
| SCHEMBL12156021 | 0.80 | CCNC (0.40) | HRH4CCNCCDK8DCTPP1NPC1 | |
| SCHEMBL12156234 | 0.77 | SMN1; SMN2 (0.40) | EGFRNUAK1NUAK2HTR6 | |
| SCHEMBL1706915 | 0.76 | ADRA2C (0.40) | HRH4DCTPP1NPC1MAPTPLOD2 | |
| SCHEMBL1705599 | 0.75 | NPC1 (0.41) | HRH4DCTPP1NPC1MAPTPLOD2 | |
| SCHEMBL2279406 | 0.72 | HTR2C (0.43) | NPC1MAPTEGFRDRD2AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2177512-B1 | INHIBITOR OF BINDING OF S1P1 | TAISHO PHARMACEUTICAL CO LTD (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-8048898-B2 | Inhibitor of binding of S1P1 | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-11-01 | — | — | US | disclosed |
| US-8048898-B2 | Inhibitor of binding of S1P1 | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-11-01 | — | — | US | disclosed |
| US-8048898-B2 | Inhibitor of binding of S1P1 | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20100234594-A1 | INHIBITOR OF BINDING OF S1P1 | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234594-A1 | INHIBITOR OF BINDING OF S1P1 | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234594-A1 | INHIBITOR OF BINDING OF S1P1 | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2177512-A1 | INHIBITOR OF BINDING OF S1P1 | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234594-A1 | INHIBITOR OF BINDING OF S1P1 | S1PR1, S1PR3, EDNRB | HRH4 103/4885CCNC 4091/4885CDK8 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.